Chrisly Dillon

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

Larisa H. Cavallari, Craig R. Lee, Amber L. Beitelshees et al. · JACC: Cardiovascular Interventions · 2017 · 310 citations

Medicine, Cardiology, Pharmacology +16

Validity of <i>International Classification of Disease</i> Codes to Identify Ischemic Stroke and Intracranial Hemorrhage Among Individuals With Associated Diagnosis of Atrial Fibrillation

Jonathan Thigpen, Chrisly Dillon, Kristen Forster et al. · Circulation Cardiovascular Quality and Outcomes · 2015 · 133 citations · Full text

Health Professions, Neurology, Clinical Classification Systems +16

Impact of the <i>CYP2C19*17</i> Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

Craig R. Lee, Cameron D. Thomas, Amber L. Beitelshees et al. · Clinical Pharmacology & Therapeutics · 2020 · 50 citations · Full text

Medicine, Cardiology, Pharmacology +17

Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data

Nita A. Limdi, Larisa H. Cavallari, Craig R. Lee et al. · The Pharmacogenomics Journal · 2020 · 44 citations · Full text

Medicine, Cardiology, Pharmacoeconomics +17

Risk of Major Adverse Cardiovascular Events and Major Hemorrhage Among White and Black Patients Undergoing Percutaneous Coronary Intervention

Anping Cai, Chrisly Dillon, William B. Hillegass et al. · Journal of the American Heart Association · 2019 · 41 citations · Full text

Medicine, Cardiology, Clinical Epidemiology +16